SEC Contract Filing

Filing Date: 2021-03-11

Document Content:
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>3
<FILENAME>onct-ex1037_578.htm
<DESCRIPTION>EX-10.37
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex1037_578.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.37</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvndnkt0ksj3000001.jpg" title="" alt="" style="width:517px;height:49px;"></p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Execution Version</font></p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 9, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">STRICTLY CONFIDENTIAL</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12230 El Camino Real</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 300</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California 92130</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: James B. Breitmeyer, M.D., Ph.D., President and Chief Executive Officer</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Dr. Breitmeyer:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.34%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This letter agreement (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) constitutes the agreement between Oncternal Therapeutics, Inc. (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;) and H.C. Wainwright &amp; Co., LLC (&#8220;<font style="text-decoration:underline;">Wainwright</font>&#8221;), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an &#8220;<font style="text-decoration:underline;">Offering</font>&#8221;) of securities of the Company (the &#8220;<font style="text-decoration:underline;">Securities</font>&#8221;) during the Term (as hereinafter defined) of this Agreement.&nbsp;&nbsp;The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities.&nbsp;&nbsp;It is understood that Wainwright&#8217;s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connection with an Offering.&nbsp;&nbsp;The Company expressly acknowledges and agrees that Wainwright&#8217;s involvement in an Offering is strictly on a reasonable best efforts basis and that the consummation of an Offering will be subject to, among other things, market conditions.&nbsp;&nbsp;The execution of this Agreement does not constitute a commitment by Wainwright to purchase the Securities and does not ensure a successful Offering of the Securities or the success of Wainwright with respect to securing any other financing on behalf of the Company.&nbsp;&nbsp;Wainwright may retain other brokers, dealers, agents or underwriters on its behalf in connection with an Offering.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compensation; Reimbursement</font>.&nbsp;&nbsp;At the closing of each Offering (each, a &#8220;<font style="text-decoration:underline;">Closing</font>&#8221;), the Company shall compensat